<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03668470</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0047</org_study_id>
    <nct_id>NCT03668470</nct_id>
  </id_info>
  <brief_title>Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes</brief_title>
  <acronym>DIAMOND GLP1</acronym>
  <official_title>Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes : A Randomized Double-blind Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some patients with type 1 diabetes (T1D) can still have some remaining insulin-positive cells
      in the pancreas and secrete little amounts of insulin. Despite the presence of residual beta
      cells, the HbA1C levels remain at high levels due to functional defects of insulin secretion
      associated with glucotoxicity. Previous trials have indicated that treatment with a
      Glucagon-like peptide 1 (GLP-1 )receptor agonist in T1D with some residual beta-cell function
      might improve glycemic control, reduce dose of insulin and risk of hypoglycemia.

      The general hypothesis of DIAMOND-GLP1 is that GLP1-R agonists will improve blood glucose

      After initial screening to select insulin microsecretors and a run-in period of one month,
      patients will be randomized into two arms and followed in parallel for 24 weeks :

        -  Experimental group receiving 1.5 mg Dulaglutide s.c weekly in addition to their usual
           insulin regimen

        -  Control group receiving placebo s.c weekly in addition to their usual insulin regimen.

      The primary endpoint is HbA1c value at 24 weeks
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicentric, investigator-initiated, randomized, double-blinded, therapeutic clinical trial, placebo-controlled, two arm parallel group intervention trial during 24 weeks, phase II.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c level</measure>
    <time_frame>after 24 weeks of treatment</time_frame>
    <description>Blood level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC us C-peptide following a MMT</measure>
    <time_frame>before and after 24 weeks of treatment</time_frame>
    <description>Evaluation and comparison before and after 24wks of treatment with Dulaglutide vs placebo the area under curve (AUC) of ultrasensitive (us) C-peptide response from 6 values following a mixed meal test (MMT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon levels fasting and following a MMT</measure>
    <time_frame>before and after 24 weeks of treatment</time_frame>
    <description>Evaluation and comparison before and after 24wks of treatment with Dulaglutide vs placebo AUC glucagon from 6 values on fasting and after MMT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC us C-peptide over AUC blood glucose levels following a MMT</measure>
    <time_frame>before and after 24 weeks of treatment</time_frame>
    <description>Evaluation and comparison the ratio of the area under curve (AUC) of us C-peptide over the glucose response following a mixed meal test (MMT) with before and after 24 weeks of treatment Dulaglutide vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily percent times spent with continuous glucose measurements (CGM) readings between 4 and 10mmol/l, above and below this range</measure>
    <time_frame>the run-in period (1 month) and after 24 weeks of treatment</time_frame>
    <description>Evaluation and comparison the changes in the daily percent time spent with continuous glucose measurements (CGM) readings between 4 and 10mmol/l during the run-in period (1 month) and after 24 weeks with Dulaglutide vs placebo, coefficients of variation (CV) and standard deviation values (SD) as well as the average daily risk change (ADRR) of glucose values to assess blood glucose variability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily insulin doses and basal/ prandial ratio</measure>
    <time_frame>: before and after 24weeks of treatment</time_frame>
    <description>Evaluation and comparison before and after 24wks of treatment with Dulaglutide vs placebo the daily insulin doses and basal/ prandial ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>: Body weight</measure>
    <time_frame>before and after 24weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% carbohydrates</measure>
    <time_frame>the run-in period (1 month) and after 24 weeks of treatment</time_frame>
    <description>Evaluate and compare the changes in mean carbohydrate intake during the run-in period and after 24 weeks with Dulaglutide vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of symptomatic hypoglycemic episodes</measure>
    <time_frame>20 months</time_frame>
    <description>Evaluation and comparison the number of symptomatic (both minor and severe) hypoglycemic episodes with Dulaglutide vs placebo during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>20 months</time_frame>
    <description>Evaluation and comparison the number of adverse events with Dulaglutide vs placebo during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autoantibodies to GAD65</measure>
    <time_frame>: before and after 24wks of treatment</time_frame>
    <description>Evaluation and comparison before and after 24wks of treatment the levels and subtypes of autoantibodies associated with T1D with and without dulaglutide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin doses : basal/ prandial ratio</measure>
    <time_frame>before and after 24weeks of treatment</time_frame>
    <description>the insulin basal/ prandial ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autoantibodies to IA-2</measure>
    <time_frame>before and after 24wks of treatment</time_frame>
    <description>Evaluation and comparison before and after 24wks of treatment the levels and subtypes of autoantibodies associated with T1D with and without dulaglutide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autoantibodies to ZnT8</measure>
    <time_frame>before and after 24wks of treatment</time_frame>
    <description>Evaluation and comparison before and after 24wks of treatment the levels and subtypes of autoantibodies associated with T1D with and without dulaglutide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>coefficients of variation (CV)</measure>
    <time_frame>the run-in period (1 month) and after 24 weeks of treatment</time_frame>
    <description>coefficients of variation (CV) of daily percent times spent with continuous glucose measurements (CGM) readings between 4 and 10mmol/l, above and below this range .</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Adult Subjects With Type1Diabetes and Insulin Microsecretion</condition>
  <arm_group>
    <arm_group_label>Dulaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group receiving 1.5 mg Dulaglutide subcutaneously weekly in addition to their usual insulin regimen during 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group receiving placebo subcutaneously weekly in addition to their usual insulin regimen during 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulaglutide</intervention_name>
    <description>Dulaglutide 1.5mg : One injection per week during 24 weeks</description>
    <arm_group_label>Dulaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: one injection per week during 24 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with T1D&gt; 4years, with age range 20-60years

          -  Diabetes onset after the age of 15years

          -  Duration of diabetes &lt;15 years

          -  Treated with continuous sub-cutaneous insulin infusions (CSI) or multiple daily
             injections of insulin (MDI)

          -  Measuring their blood sugar at least four times daily

          -  Glycated hemoglobin (HbA1C) at screening &gt;7 and &lt;10%

          -  16.0 kg/m2 &lt;BMI&lt;30.0kg/m2

          -  Patients with childbearing potential should use effective contraception, defined as
             methods with a failure rate ≤ 2 % per year (OMS 2011) during the study.

          -  Patients who gave its written informed consent to participate to the study

          -  Patients affiliated to a social insurance regime

        Randomization criteria:

        Patients with fasting ultra-sensitive (us) C-peptide above 15pmol/l

        Exclusion Criteria:

          -  Patients are not eligible for this study if any of the following exclusion criteria
             apply:

          -  Patients with type 2 diabetes (T2D)

          -  Hypersensitivity to dulaglutide and/or any of its excipients

          -  Subjects with history of severe hypoglycemia or recent (&lt; 6 months) history of
             diabetic ketoacidosis

          -  History of gastrointestinal disease with prolonged (&gt; 3 months) nausea or vomiting,
             liver or kidney diseases, pancreatitis, thyroid medullary cancer or familial history
             of multiple endocrine neoplasia type 2

          -  Estimated glomerular filtration rate&lt;60ml/min/ 1.73m2 (CKD-EPI method)

          -  Congestive heart failure

          -  Any uncontrolled disease, cancers essentially

          -  Chronic use of paracetamol containing products, which may falsely raise sensor glucose
             readings

          -  Use of tricyclic antidepressant, selective serotonin reuptake inhibitor, triptans,
             neuroleptic drugs and glucocorticoid.

          -  Patient who participated in another clinical trial on experimental drug in the
             previous 30 days

          -  Patients of childbearing potential who are not using adequate contraception; Female
             patients who are pregnant or lactating.

          -  Gastric bypass surgery

          -  Patients under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles THIVOLET</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles THIVOLET</last_name>
    <phone>+33 4 78 86 14 87</phone>
    <email>charles.thivolet@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service d'Endocrinologie, Maladies Métaboliques et Nutrition, CHU Grenoble, Hopital de la Tronche</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre-Yves BENHAMOU</last_name>
      <phone>+33 4 76 76 55 09</phone>
      <email>PYBenhamou@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-Yves BENHAMOU</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine LABLANCHE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Département d''Endocrinologie, Diabétologie, Nutrition ; CHU Montpellier ; Hôpital Lapeyronie, Avenue du Doyen Giraud</name>
      <address>
        <city>Montpellier 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric RENARD</last_name>
      <phone>+33 4 67 33 83 82</phone>
      <email>e-renard@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Eric RENARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne WOJTUSCISZYN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie, Maladies Métaboliques et Nutrition,CHU Nantes,Hôpital Nord Laennec,Bd Jacques-Monod,Saint-Herblain</name>
      <address>
        <city>NANTES cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand CARIOU</last_name>
      <phone>+33 2 53 48 27 01</phone>
      <email>bertrand.cariou@univ-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Bertrand CARIOU</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucy CHAILLOUS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Diabétologie et Maladies Métaboliques, Assistance Publique des Hôpitaux de Paris ;Hôpital Cochin, 27 rue du Faubourg Saint-Jacques</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne LARGER</last_name>
      <phone>+33 1 58 41 19 19</phone>
      <email>etienne.larger@cch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Etienne LARGER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie, Diabétologie, Maladies de la Nutrition, Hospices Civils de Lyon, Centre hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles THIVOLET</last_name>
      <phone>+33 4 78 86 14 87</phone>
      <email>charles.thivolet@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Charles THIVOLET</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucien MARCHAND</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Diabétologie Maladies Métaboliques et Nutrition ; CHU Toulouse, Pôle cardiovasculaire et métabolique, Hôpital Rangueil ; 1, avenue du Professeur Jean Poulhès - TSA 50032</name>
      <address>
        <city>TOULOUSE cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène HANAIRE</last_name>
      <phone>: +33 5 61 32 30 18</phone>
      <email>hanaire.h@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Hélène HANAIRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Diabétologie, Maladies Métaboliques, Nutrition ; CHU Nancy ; Technopôle Nancy-Brabois ; Rue du Morvan,</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno GUERCI</last_name>
      <phone>+33 3 83 65 65 28</phone>
      <email>b.guerci@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno GUERCI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 1 diabetes</keyword>
  <keyword>insulin microsecretion</keyword>
  <keyword>dulaglutide</keyword>
  <keyword>randomized</keyword>
  <keyword>double-blind placebo-controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dulaglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

